Back to Search
Start Over
Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia
- Source :
- Expert Opinion on Drug Safety. 21:9-20
- Publication Year :
- 2021
- Publisher :
- Informa UK Limited, 2021.
-
Abstract
- Introduction: Inclisiran is a novel posttranscriptional gene silencing therapy that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) synthesis by RNA interference and has a potent, dose-dependent, durable effect in lowering LDL-C, and therefore is an effective drug to treat dyslipidemia, reducing the risk for acute cardiovascular (CV) events. It is safe and well-tolerated. Areas covered: This paper aims to review the mechanism of action of inclisiran while evaluating its efficacy and safety in the treatment of dyslipidemia from data of the clinical trials in the ORION program. Expert opinion: Data from the clinical trials in the ORION program demonstrated efficacy and safety of inclisiran in patients with dyslipidemia. Adverse events were similar in the inclisiran and placebo groups in the clinical trials, although injection-site reactions were more frequent with inclisiran than with placebo. Although the combination of efficacy and safety makes inclisiran a good option for the treatment of dyslipidemia compared to other PCSK9 targeting therapeutic strategies, however, further studies should exclude the possibility that inclisiran, through lower-affinity interactions, may influence other mRNAs in the physiological milieu.
- Subjects :
- Drug
Small interfering RNA
media_common.quotation_subject
Hypercholesterolemia
Placebo
Bioinformatics
LDL
PCSK9
RNA interference
medicine
Animals
Humans
Pharmacology (medical)
Gene Silencing
RNA, Small Interfering
Adverse effect
Dyslipidemias
media_common
therapy
business.industry
General Medicine
medicine.disease
Clinical trial
Cardiovascular Diseases
Atherosclerosis, inclisiran, LDL, PCSK9, RNA, therapy, Animals, Cardiovascular Diseases, Dyslipidemias, Gene Silencing, Humans, Hypercholesterolemia, Proprotein Convertase 9, RNA, Small Interfering
Atherosclerosi
RNA
Proprotein Convertase 9
business
inclisiran
Dyslipidemia
Subjects
Details
- ISSN :
- 1744764X and 14740338
- Volume :
- 21
- Database :
- OpenAIRE
- Journal :
- Expert Opinion on Drug Safety
- Accession number :
- edsair.doi.dedup.....a008fe9ea51505dc2fead510398c85fe